Therapy of hepatitis C in patients with HIV infection

References

• Mohsen AH, Easterbrook P, Taylor CB et al. Hepatitis C and HIV-1 coinfection. Gut 51(4), 601–608 (2002).
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N. Engl. J. Med. 338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Bica I, McGovern B, Dhar R et al. Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32(3), 492–497 (2001).
   PubMed Web of Science ®Google Scholar
• Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362(9397), 1708–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Bonacini M, Louie S, Bzowej N et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 18(15), 2039–2045 (2004).
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 26(1), 1–5 (1997).
   PubMed Web of Science ®Google Scholar
• Sanchez-Quijano A, Andreu J, Gavilan F et al. Influence of human immunodeficiency virus Type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur. J. Clin. Microbiol. Infect. Dis. 14(11), 949–953 (1995).
   PubMed Web of Science ®Google Scholar
• Di Martino V, Rufat P, Boyer N et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34(6), 1193–1199 (2001).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30(4), 1054–1058 (1999).
   PubMed Web of Science ®Google Scholar
• Macias JCV, Merchante N, Palacios RB et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18, 767–774 (2004).
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34(2), 283–287 (2001).
   PubMed Web of Science ®Google Scholar
• Puoti M, Spinetti A, Putzolu V et al. HIV-HCV Coinfection Study Group. Liver fibrosis progression is related to CD4+ cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect. Dis. 183(1), 134–137 (2001).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Chaisson RE et al. Hepatitis C and progression of HIV disease. J. Am. Med. Assoc. 288(2), 199–206 (2002).
   PubMed Web of Science ®Google Scholar
• Rancinan C, Saves M, Lawson-Ayayi S et al., and the Groupe d’Epidemiologie Clinique du SIDA en Aquitaine. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 16(10), 1357–1362 (2002).
   PubMed Web of Science ®Google Scholar
• Grueb G, Battegay M, Grob P et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coninfection: the Swiss HIV Cohort Study. Lancet 356, 1800–1805 (2000).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Dramer J, Richardson P et al. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin. Gastroenterol. Hepatol. 3, 175–183 (2005).
   PubMed Web of Science ®Google Scholar
• Restrepo A, Johnson TC, Widjaja D et al. The rate of treatment of hepatitis C in patients co-infected with HIV in an urban medical center. Dig. Dis. Wk (2003) (Abstract M1625).
   Google Scholar
• National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Hepatology 36(5 Suppl. 1), S3–S20 (2002).
   PubMed Web of Science ®Google Scholar
• Bonacini M, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J. Acquir. Immune Defic. Syndr. 26(4), 340–344 (2001).
   PubMed Web of Science ®Google Scholar
• George SL, Gebhardt J, Klinzman D et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J. Acquir. Immune Defic. Syndr. 31, 154–162 (2002).
   PubMed Web of Science ®Google Scholar
• Poles MA, Dieterich DT, Schwarz ED et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11(2), 170–177 (1996).
   PubMedGoogle Scholar
• Soriano V, Sulkowski M, Mauss S et al. Care of patients with hepatitis C and HIV co-infection. AIDS 18(1), 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon-α2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438–450 (2004).
   PubMed Web of Science ®Google Scholar
• Soriano V, Garcia-Samaniego J, Bravo R et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin. Infect. Dis. 23(3), 585–591 (1996).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon -2b plus ribavirin compared with interfero-α2a plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon-α2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Afdhal N. Colchicine versus Peg-Intron Long-term (COPILOT) Trial: interim analysis of clinical outcomes at year 2. 55th Annual meeting of the American Association for the Study of Liver Disease (AASLD) (2004).
   Google Scholar
• Mauss S, Valenti W, DePamphilis J et al., Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 18(13), F21–F25 (2004).
   Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140(5), 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P et al. Peginterferon Alfa-2a plus ribavirin versus interferon-α2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451–459 (2004).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Poynard T, Pianko S et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119(5), 1317–1323 (2000).
   PubMed Web of Science ®Google Scholar
• Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30(3), 787–793 (1999).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated-interferon- α2a vs. standard interferon-α2a, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. J. Am. Med. Assoc. 292, 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Blanco JL, Martinez E et al. Peginterferon-α2a plus ribavirin compared with interferon- α2a plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18, F27–F36 (2004).
   Google Scholar
• Núñez, M, Berdún MA, Losada E et al. Efficacy and Safety of Peginterferon-α2a (40 kD) plus Ribavirin (PEG-IFN-α2a + RBV) for the Treatment of Hepatitis C in HIV Co-infected Patients: Interim results of the PRESCO Trial. In: First international workshop on HIV and Hepatitis C Co-infection. Amsterdam, The Netherlands (2004).
   Google Scholar
• Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 12(10), 1256 (1998).
   PubMed Web of Science ®Google Scholar
• Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin. Liver Dis. 23(2), 167–172 (1998).
   Google Scholar
• Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver Dis. 23(2), 183–194 (2003).
   PubMed Web of Science ®Google Scholar
• Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin. Liver Dis. 23(2), 173–182 (2003).
   PubMed Web of Science ®Google Scholar
• Baba M, Pauwels R, Balzarini J et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2’,3’-dideoxynucleosides but enhances inhibitory effects of purine 2’,3’-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31(10), 1613–1617 (1987).
   PubMed Web of Science ®Google Scholar
• Vogt MW, Hartshorn KL, Furman PA et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235(4794), 1376–1379 (1987).
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357(9252), 280–281 (2001).
   PubMed Web of Science ®Google Scholar
• Brau N, Rodriguez-Torres M, Prokupek D et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon-α2a+ full-course vs. 16-week delayed ribavirin. Hepatology 39(4), 989–998 (2004).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J. Am. Med. Assoc. 283(1), 74–80 (2000).
   PubMed Web of Science ®Google Scholar
• Gergely AE, Lafarge P, Fouchard-Hubert I et al. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 35(5), 1281–1282 (2002).
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Wasserman R, Brau N et al. Once-weekly epoetin-α improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon-α. Am. J. Gastroenterol. 98(11), 2491–2499 (2003).
   PubMed Web of Science ®Google Scholar
• Carreno V, Parra A, Navas S et al. Granulocyte-macrophage colony-stimulating factor as adjuvant therapy for factor as adjuvant therapy for interferon alpha treatment of chronic hepatitis C. Cytokine 8(4), 318–322 (1996).
   PubMed Web of Science ®Google Scholar
• Golia P, Jacobson IM, Flynn S, Golia P. A preliminary study of growth factors versus dose reduction for peg interferon-α2a and ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients. Gastroenterology 124(Suppl. 1), A766 (2003).
   Google Scholar
• Mauss S, Klinker H, Ulmer A et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 26(1), 16–19 (1998).
   PubMed Web of Science ®Google Scholar
• Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol. 3(1), 8 (2004).
   PubMedGoogle Scholar
• McHutchison JG, Gordon SC, Schiff ER et al. Interferon-α2a alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339(21), 1485–1492 (1998).
   PubMed Web of Science ®Google Scholar
• Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 36(5 Suppl. 1), S185–S194 (2002).
   Google Scholar
• Crippin JS, McCashland T, Terrault N et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 8(4), 350–355 (2002).
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon-α2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343(23), 1673–1680 (2000).
   Google Scholar
• Everson GT, Jensen DM, Craig JR et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 30(1), 271–276 (1999).
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon-α2a and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122(5), 1303–1313 (2002).
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352(9138), 1426–1432 (1998).
   PubMed Web of Science ®Google Scholar
• Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end stage liver disease. Liver Transpl. 9(3), 239–247 (2003).
   PubMed Web of Science ®Google Scholar